CAR-T cell therapy has revolutionized the treatment of blood cancers, earning regulatory approval and delivering impressive results in hematologic malignancies. However, its success has not yet translated to solid tumors, where it continues to face significant challenges and limited long-term efficacy. As a result, ongoing CAR-T development remains largely focused on blood cancers.
In contrast, bispecific antibodies have emerged as a versatile and promising class of therapeutics, securing approvals for both blood cancers and solid tumors. Notably, they have shown more consistent and durable responses in solid tumor settings. Current research and development in the ...
